Lp(a) could be a useful screening biomarker to identify vulnerable patients with coronary artery disease (CAD) who are currently underdiagnosed, such as those without modifiable cardiovascular risk factors, suggest cardiology researchers.
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
